Compliance of elderly head and neck squamous cell carcinoma (HNSCC) patients (pts) with concurrent chemoradiotherapy (CRT) in cetuximab versus cisplatin.

• DOI: 10.1200/jco.2017.35.15_suppl.e17553
• Publication Date: 2018-09-06T15:47:30Z
• Authors: Eyad Kazan; Tiffanie Kleihneny; Nacera Sakek; Alice Thomas; Lucia Milian; Magali Edel
• Keywords: Chemoradiotherapy

e17553 Background: Cisplatin toxicities substantially increased in elderly patients with head and neck cancer, when it is given as CRT. Bio-radiotherapy using cetuximab could offer a less toxic alternative. The purpose of this retrospective study to evaluate the compliance versus cisplatin CRT for HNSCC pts 70 years age or old pts. Methods: We included over treated by radio chemotherapy cancer. Severity AE was measured percentage drug dose reduction. Dose considered reduced if patient did not receive 200mg/m² group, he seven planned cycles group. recalculated reduction including 65 patientes. Results: enrolled 37 pts, middle 74.5(from 88). 23 were cetximab-RT compared 14 cisplatin-RT. 30% (7 pts) cet-RT group received 28% (4 cisplatin-RT Then, comparable close.This finding disclaim general assumption that better tolerated than concurrently radiotherapy When we also endrolled 64 remains about (10 35pts) only 17% (5 29) A clear increasing appears once passed old. Finally, redistributed 35 cetuximab-RT according period treatment, first between 2007 2011, 35% 20patients),the second 2012 2016, 20% (3 15). This supports good handling cetuximab's improves treatment's compliance. Conclusions: equal cisplatin. clearly increases among 70years Good treatment